Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Miltefosine Zentaris.

Ronald Kaminsky1

  • 1Novartis, Centre de Recherche Santé Animale SA,, St. Aibin, Switzerland. ronald.kaminsky@ah.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global impact of parasitic infections and the importance of parasite control.

Frontiers in parasitology·2025
Same author

Heartworm disease - Overview, intervention, and industry perspective.

International journal for parasitology. Drugs and drug resistance·2021
Same author

World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) guidelines for studies evaluating the efficacy of parasiticides in reducing the risk of vector-borne pathogen transmission in dogs and cats.

Veterinary parasitology·2021
Same author

Where Is the Breakthrough Innovation for Parasite Control?

Trends in parasitology·2017
Same author

Blocking transmission of vector-borne diseases.

International journal for parasitology. Drugs and drug resistance·2017
Same author

Macrocyclic lactone resistance in Dirofilaria immitis: Failure of heartworm preventives and investigation of genetic markers for resistance.

Veterinary parasitology·2015
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Miltefosine, a phospholipid derivative, is available in Europe and Brazil for breast cancer treatment. Ongoing Phase III trials in 2002 explored its potential for treating leishmaniasis.

Area of Science:

  • Pharmacology
  • Oncology
  • Infectious Diseases

Background:

  • Miltefosine, a phospholipid derivative developed by Zentaris, has been launched in European countries and Brazil.
  • It was initially approved for breast cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of miltefosine for breast cancer.
  • To investigate miltefosine as a potential treatment for leishmaniasis.

Main Methods:

  • Phase III clinical trials were conducted for leishmaniasis treatment as of January 2002.
  • Data from European and Brazilian launches for breast cancer were considered.

Main Results:

  • Miltefosine was launched for breast cancer treatment in various European countries and Brazil.

Related Experiment Videos

  • Phase III trials for leishmaniasis were underway in early 2002.

    • Conclusions:

    • Miltefosine demonstrated utility in breast cancer treatment.
    • Further clinical evaluation was ongoing to establish miltefosine as a treatment for leishmaniasis.